Translate Bio to Present at the Bank of America Securities Virtual 2020 Healthcare Conference
13 May 2020 - 6:05AM
Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA)
therapeutics company developing a new class of potentially
transformative medicines to treat diseases caused by protein or
gene dysfunction, today announced that Ronald Renaud, chief
executive officer, will participate in a fireside chat at the Bank
of America Securities Virtual 2020 Health Care Conference on
Thursday, May 14, 2020, at 9:00 a.m. ET.
A live webcast of the session will be accessible
through the “Events and Presentations” page of the Company's
website at investors.translate.bio. A replay of the webcast will be
archived on the Translate Bio’s website for 30 days following the
presentation.
About Translate BioTranslate
Bio is a clinical-stage mRNA therapeutics company developing a new
class of potentially transformative medicines to treat diseases
caused by protein or gene dysfunction. Translate Bio is
primarily focused on applying its technology to treat pulmonary
diseases caused by insufficient protein production or where the
reduction of proteins can modify disease. Translate Bio’s
lead program is being developed as a treatment for cystic fibrosis
(CF) and is in a Phase 1/2 clinical trial. The Company also
believes its technology is applicable to a broad range of diseases,
including diseases that affect the liver. Additionally, the
platform may be applied to various classes of treatments, such as
therapeutic antibodies or vaccines in areas such as infectious
disease and oncology. For more information about the Company,
please visit www.translate.bio or on Twitter at @TranslateBio.
Contacts for Translate Bio
Investors |
|
Media |
Teri Dahlman |
|
Maura Gavaghan |
tdahlman@translate.bio |
|
mgavaghan@translate.bio |
857-242-7792 |
|
857-242-7789 |
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From Apr 2024 to May 2024
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From May 2023 to May 2024